PURPOSE: To determine whether exercise training would increase lymphocyte activation in patients with breast cancer following chemotherapy. Activation was determined by the presence of CD4(+)CD69(+) T-helper lymphocytes, mitogen-induced proliferation, and levels of cytokines produced by mitogen-stimulated lymphocytes and in the patients' plasma. METHODS: Patients with breast cancer (N = 28) who participated in a 6-month exercise program were compared with patients (N = 21) who did not exercise. Following chemotherapy, and 3 and 6 months later, patients underwent fitness evaluations and had blood drawn. The exercise program consisted of resistance training and aerobic activity at 60-75% functional capacity three times a week with a personal trainer. Immunochemistry and flow cytometry were used to measure the number of CD4(+)CD69(+) blood lymphocytes. Whole blood was stimulated with concanavalin A (ConA), phytohemagglutin (PHA), or pokeweed mitogen (PWM) to determine proliferation potential. Enzyme-linked immunosorbent assays (ELISA) were used to determine the concentration of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) in the culture medium of mitogen-stimulated lymphocytes as well as the plasma concentrations of IL-6, soluble IL-6 receptor, soluble gp130, and IFN-gamma. Analysis of groups across time was done using the Wilcoxon signed rank test, and comparisons of groups were done using the Mann-Whitney U test. RESULTS: The exercising patients showed increases in maximal oxygen uptake and upper body strength. This group also showed a greater percentage of CD4(+)CD69(+) cells and a greater level of tritiated thymidine incorporation (DNA synthesis) when stimulated with ConA, PHA, and PWM at the end of the intervention. Plasma and mitogen-stimulated IL-6 and IFN-gamma production were similar in both groups. CONCLUSION: Exercise may improve immune function by increasing lymphocyte activation in patients with breast cancer following treatment.
PURPOSE: To determine whether exercise training would increase lymphocyte activation in patients with breast cancer following chemotherapy. Activation was determined by the presence of CD4(+)CD69(+) T-helper lymphocytes, mitogen-induced proliferation, and levels of cytokines produced by mitogen-stimulated lymphocytes and in the patients' plasma. METHODS:Patients with breast cancer (N = 28) who participated in a 6-month exercise program were compared with patients (N = 21) who did not exercise. Following chemotherapy, and 3 and 6 months later, patients underwent fitness evaluations and had blood drawn. The exercise program consisted of resistance training and aerobic activity at 60-75% functional capacity three times a week with a personal trainer. Immunochemistry and flow cytometry were used to measure the number of CD4(+)CD69(+) blood lymphocytes. Whole blood was stimulated with concanavalin A (ConA), phytohemagglutin (PHA), or pokeweed mitogen (PWM) to determine proliferation potential. Enzyme-linked immunosorbent assays (ELISA) were used to determine the concentration of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) in the culture medium of mitogen-stimulated lymphocytes as well as the plasma concentrations of IL-6, soluble IL-6 receptor, soluble gp130, and IFN-gamma. Analysis of groups across time was done using the Wilcoxon signed rank test, and comparisons of groups were done using the Mann-Whitney U test. RESULTS: The exercising patients showed increases in maximal oxygen uptake and upper body strength. This group also showed a greater percentage of CD4(+)CD69(+) cells and a greater level of tritiated thymidine incorporation (DNA synthesis) when stimulated with ConA, PHA, and PWM at the end of the intervention. Plasma and mitogen-stimulated IL-6 and IFN-gamma production were similar in both groups. CONCLUSION: Exercise may improve immune function by increasing lymphocyte activation in patients with breast cancer following treatment.
Authors: Rebecca M Speck; Kerry S Courneya; Louise C Mâsse; Sue Duval; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2010-01-06 Impact factor: 4.442
Authors: Thorsten Schmidt; Walter Jonat; Daniela Wesch; Hans-Heinrich Oberg; Sabine Adam-Klages; Lisa Keller; Christoph Röcken; Christoph Mundhenke Journal: J Cancer Res Clin Oncol Date: 2018-01-05 Impact factor: 4.553
Authors: Freerk T Baumann; Wilhelm Bloch; Anke Weissen; Marie Brockhaus; Julia Beulertz; Philipp Zimmer; Fiona Streckmann; Eva M Zopf Journal: Breast Care (Basel) Date: 2013-10 Impact factor: 2.860
Authors: Christina M Dieli-Conwright; Jean-Hugues Parmentier; Nathalie Sami; Kyuwan Lee; Darcy Spicer; Wendy J Mack; Fred Sattler; Steven D Mittelman Journal: Breast Cancer Res Treat Date: 2017-11-22 Impact factor: 4.872
Authors: Sue Kim; Yun Hee Ko; Yoonkyung Song; Min Jae Kang; Hyojin Lee; Sung Hae Kim; Justin Y Jeon; Young Up Cho; Gihong Yi; Jeehee Han Journal: Support Care Cancer Date: 2020-02-26 Impact factor: 3.603
Authors: Sara B Jones; Gwendolyn A Thomas; Sara D Hesselsweet; Marty Alvarez-Reeves; Herbert Yu; Melinda L Irwin Journal: Cancer Prev Res (Phila) Date: 2012-12-04